Nonapeptide-1 vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Nonapeptide-1GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- Not applicable (topical)
- ~13 hours (once-daily dosing)
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 0.05–0.5% concentration in formulation
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Twice daily
- Once daily
- Key Benefits
- Inhibits UV-induced tanning and hyperpigmentation
- Reduces hormonal melasma
- Evens skin tone at receptor level
- Well-tolerated with minimal irritation
- Complementary to tyrosinase inhibitors for enhanced brightening
- Reduces post-inflammatory hyperpigmentation
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Generally very well-tolerated
- Rare contact sensitivity in susceptible individuals
- Theoretical risk of excessive depigmentation with prolonged high-concentration use
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —